Cancer cells can suppress immune responses, limiting the long-term effectiveness of immunotherapy. This research shows that monocytes—key immune cells—can be “trained” using metabolites to become more effective at attacking cancer. Understanding and harnessing this trained immunity could improve immunotherapy outcomes and help predict which patients benefit most from treatment.